Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.780
+0.180 (5.00%)
At close: Jul 2, 2026, 4:00 PM EDT
3.793
+0.013 (0.34%)
After-hours: Jul 2, 2026, 7:52 PM EDT
Voyager Therapeutics Employees
Voyager Therapeutics had 141 employees as of December 31, 2025. The number of employees decreased by 31 or -18.02% compared to the previous year.
Employees
141
Change (1Y)
-31
Growth (1Y)
-18.02%
Revenue / Employee
$258,823
Profits / Employee
-$827,213
Market Cap
228.39M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 141 | -31 | -18.02% | 141 | 0 |
| Dec 31, 2024 | 172 | 10 | 6.17% | 172 | 0 |
| Dec 31, 2023 | 162 | 37 | 29.60% | 162 | 0 |
| Dec 31, 2022 | 125 | 24 | 23.76% | 125 | 0 |
| Dec 31, 2021 | 101 | -78 | -43.58% | 101 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 146 |
| Coherus Oncology | 145 |
| Nkarta | 108 |
| Alector | 103 |
| Keros Therapeutics | 87 |
| Camp4 Therapeutics | 48 |
| Protara Therapeutics | 46 |
| Whitehawk Therapeutics | 29 |
VYGR News
- 4 days ago - Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 - GlobeNewsWire
- 18 days ago - Voyager Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 22 days ago - Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference - GlobeNewsWire
- 24 days ago - Voyager Therapeutics Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Voyager Therapeutics announces FDA clearance for VY1706 IND application - TheFly
- 4 weeks ago - Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease - GlobeNewsWire
- 7 weeks ago - Voyager Therapeutics presents GLP for toxicology data for VY1706 - TheFly
- 7 weeks ago - Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 - GlobeNewsWire